Black-Box Medicine: Legal and Ethical Issues image

February 8, 2019 12:00 PM
Lectures and Panels
2018-2019
Harvard Law School, Wasserstein Hall, Milstein East C (2036)
1585 Massachusetts Ave., Cambridge, MA

Register for this event

Description

Black-box medicine—the use of opaque computational models to make care decisions—has the potential to shape health care by improving and aiding many medical tasks. For example, IBM Watson for Oncology is a machine-learning system that intends to help clinicians quickly identify essential information in patients’ medical records and explore treatment options for 13 cancers. However, it has only recently emerged that the recommendations Watson for Oncology gave for cancer treatments were “often incorrect” and that IBM kept this defect secret for over a year. What are the ethical and legal issues of black-box medicine? When do algorithms operate like a “black box“? How can we ensure that artificial intelligence technologies deliver what they promise?

This event is free and open to the public, but seating is limited and registration is required. Register now!

Panelists

  • I. Glenn Cohen, Faculty Director and James A. Attwood and Leslie Williams Professor of Law, Harvard Law School and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School

  • Ziad Obermeyer, Acting Associate Professor, Health Policy and Management, University of California, Berkeley, School of Public Health

  • Moderator: Carmel ShacharExecutive Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and Lecturer on Law, Harvard Law School

The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations. 

They are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.

Tags

ai   bioethics   biotechnology   genetics   health law policy   health policy and bioethics consortia   intellectual property   medical safety   regulation